Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 341

Posts Tagged ‘dermatology’

Almirall partners with Plug and Play to accelerate digital innovation in dermatology

Posted by fidest press agency su domenica, 9 febbraio 2020

Almirall, S.A. (ALM), a leading skin-health focused global pharmaceutical company, and Plug and Play, a leading health tech accelerator and innovation platform, announced a partnership today to boost digital innovation in dermatology. Through this collaboration, Almirall will enter into the Plug and Play Health program and gain access to the largest health innovation ecosystem globally, including stakeholders and startups. This collaboration will reinforce the reach of the Digital Garden powered by Almirall, a dermatology digital health startup innovation platform, increasing access to the dynamic resources of its stakeholders and resources in Silicon Valley, in addition to Plug and Play events. The Digital Garden, based in the Barcelona Health Hub, has selected 5 startups that will participate in a 9-month program focused on developing innovative technology-based services and solutions to accelerate their go-to-market plans and to tackle some of the biggest dermatological challenges of today and in the future.According to Francesca Wuttke, Chief Digital Officer of Almirall: “the partnership with Plug and Play´s Health Program opens a door for Almirall to connect with a wider range of dermatological innovation start-ups all over the world, which will boost our Digital Garden and, at the same time, will allow Almirall to contribute to the digital evolution of this ecosystem, by offering patient centric services and solutions that combine technology and medicine to empower patients and providers.”Plug and Play’s Health program connects forward-thinking corporations and investors with startups in the health industry around topics such as digital health, nutrition, patient engagement, and improved outcomes. Each year, Plug and Play Health accelerates hundreds of startups in their Health-focused hubs in Silicon Valley, Cleveland, Singapore, Shanghai and Kyoto. These young companies are then connected with sponsoring organizations like Almirall for business development and investment opportunities.”We are excited to welcome Almirall as the first dermatology-focused partner in our Health Program along with leading corporations such as Roche, Novartis, Cleveland Clinic, Boehringer Ingelheim, Sanofi, and Amgen. We look forward to supporting the Digital Garden activities in Barcelona as well as providing access to our global innovation ecosystem for Almirall and their program’s start-ups”, says Julia Belaya, Global Head of Business Development of Plug and Play Health.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Almirall launches the accelerator Digital Garden to drive digital innovation in dermatology

Posted by fidest press agency su lunedì, 18 novembre 2019

Almirall, S.A. (ALM) today announced the launch of the Digital Garden, a dermatology digital health accelerator focused on developing innovative technology-based services and solutions to accelerate their go-to-market plans and tackling some of the dermatology challenges today and in the future. The selection of the first cohort of the Digital Garden has been selected in a pitch event held at the Frontiers Health annual event in Berlin.In October, Almirall announced the launch of a first call for innovation to start-ups focused on digital innovations in medical dermatology. Since then more than 40 start-ups have shown interest to join the program via almiralldigitalgarden.com. Almirall preselected eight of them from among the many applicants to present their business model to an expert investor jury. The five winning projects will join a nine-month accelerator program starting in January at the Barcelona Health Hub.
In addition, the Digital Garden, powered by Almirall will also provide mentoring from top healthcare experts from Almirall and the potential to collaborate on actual projects within the company. The acceleration program includes the opportunity to leverage leading hospitals in Barcelona as a test bed for digital pilots, with potential access to HCPs and patients. The Digital Garden is not requiring an equity component from the start-ups, but rather will be finding up to € 50.000 based on milestones agreed between Almirall and the start-ups.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

24th World Congress of Dermatology

Posted by fidest press agency su mercoledì, 22 maggio 2019

Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24th World Congress of Dermatology (WCD). This meeting will be held in Milan, Italy from June 10-15, 2019.
Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients with vitiligo, which will be highlighted during the late-breaking research session, and 12-week data from a Phase 2 study of ruxolitinib cream in adult patients with atopic dermatitis.“We look forward to sharing initial results from our Phase 2 study of ruxolitinib cream in vitiligo and additional data from our Phase 2 trial in atopic dermatitis – two conditions for which many patients need novel and effective treatment options,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Incyte is committed to developing therapies to address key unmet medical needs, and data to be presented at WCD demonstrate exciting progress in the development of ruxolitinib cream, our most advanced inflammation and autoimmunity program.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

AlmirallShare, a successful platform to find innovative solutions in medical dermatology

Posted by fidest press agency su lunedì, 11 febbraio 2019

AlmirallShare, the open innovation R&D platform of Almirall, S.A. (ALM), has attracted the attention of scientists from universities, research centres, and start-ups interested in dermatological research, proving to be a successful platform designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in medical dermatology. To date, over 450 scientists from all continents have subscribed to AlmirallShare and over 170 different proposals have been received.
AlmirallShare addresses challenges such as the identification of therapeutic targets and experimental disease models, the development of new therapeutic treatments as well as novel technologies in dermatology. These challenges are translated into Calls for Proposals (CFPs) that are published on AlmirallShare web page (sharedinnovation.almirall.com), so that scientists from all continents can submit their proposals for collaborations.Since its launch in September 2017, we have issued three CFPs. The first CFP was focused on increasing the understanding of skin pathology in our core diseases by funding the development of translational preclinical models.In 2018, we issued the CFP ‘Adding Value to Your Assets’ to find a use for existing advanced small molecules in the therapeutic treatment of diseases. It will be open on permanent basis. The most recent CFP, ‘Novel Targets for Skin Health’, offered research funding for work on novel targets that may form the basis for new medicines in dermatological diseases. It is open until the end of February 2019.Outstanding results of 2018 are the establishment of two research partnerships on preclinical models for atopic dermatitis. We have funded research by Professor Dr. Günther Eissner, Principal Investigator of Translational Systems Biology, and Dr. Leila Smith, from the System Biology Ireland, at the University College Dublin (Ireland) on the development of a novel atopic dermatitis murine model. The work by Professor Craig Murdoch, Dr. Helen Colley and Dr. Simon Dandy from the University of Sheffield (UK) on the development of an immune competent human skin equivalent model of atopic dermatitis for preclinical drug testing has also been supported. On top of that, two biotech companies have been identified as new providers of state-of-the-art experimental models.“We are excited about AlmirallShare results achieved so far. We have started our journey to develop new therapies for medical dermatology sharing Science and innovation with the Scientific community”, said Maribel Crespo, AlmirallShare Leader. “AlmirallShare is helping to advance our R&D strategy, focused on delivering true breakthrough innovation and real differentiation for patients and healthcare professionals”.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Global Dermatology Drugs Market to 2023

Posted by fidest press agency su martedì, 22 agosto 2017

psoriasiThe report Global Dermatology Drugs Market to 2023 – Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Data from Tildrakizumab Clinical Development Program Presented at the 2017 American Academy of Dermatology Meeting

Posted by fidest press agency su mercoledì, 8 marzo 2017

barcelonaBarcelona, Spain, March 7, 2017 – Almirall S.L (Spanish Stock Exchange ticker: ALM) and Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries or associate companies), today announced that several new analyses from Phase-I and the pivotal Phase-III clinical trials (reSURFACE 1 and 2) of Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, was presented at the 2017 Annual American Academy of Dermatology (AAD) in Orlando, Florida.
Over 1,800 patients across more than 200 clinical sites participated in the Tildrakizumab Phase-III pivotal trials (reSURFACE 1 and 2). Data were presented for the first time demonstrating results through 28 weeks of treatment at the European Academy of Dermatology and Venerology (EADV) Congress in October 2016. Regulatory filings for Tildrakizumab in the U.S. and Europe are proceeding as planned.
Psoriasis is a chronic immune disease that appears on the skin. It affects an estimated 7.5 million people in the U.S. and approximately 125 million people worldwide1. It is a non-contagious disorder that speeds the growth cycle of skin cells1 and results in thick scaly areas of skin2. The most common form of Psoriasis, called plaque Psoriasis, appears as red, raised areas of skin covered with flaky white scales, which may be itchy and painful and can crack and bleed2. Despite existing treatment options, many people with plaque psoriasis continue to struggle with the ongoing, persistent nature of this chronic disease.
Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. With this precise targeting, Tildrakizumab has the potential to help control the pathogenic cells responsible for the inflammatory process of Psoriasis with limited impact on.the rest of the immune system. Phase-III Tildrakizumab data provide further evidence for the role of the Sun Pharma is committed to expanding our dermatology portfolio to bring healthcare providers and patients around the world more treatment options and ongoing support for conditions with high unmet medical needs like Psoriasis. Sun Pharma, along with its subsidiaries, is ranked fourth in dermatology prescription volume within the U.S. per IMS and is fifth largest specialty generic pharmaceutical company globally. In addition to the investigational candidate Tildrakizumab, an investigational anti-IL- 23p19 monoclonal antibody, Sun Dermatology is comprised of several branded products indicated for the treatment of acne and actinic keratosis with a focus on other dermatologic conditions with unmet needs such as Psoriasis and atopic dermatitis.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Studio EGALITY sul British Journal of Dermatology

Posted by fidest press agency su domenica, 27 novembre 2016

novartis-sedeHolzkirchen. Sandoz, divisione del gruppo Novartis, pioniera e leader globale dei farmaci biosimilari, annuncia in questi giorni la pubblicazione dello studio EGALITY sul British Journal of Dermatology. Lo studio clinico ha dimostrato sicurezza, efficacia ed immunogenicità equivalenti tra il biosimilare Etanercept di Sandoz ed il prodotto di riferimento, Enbrel®. Lo studio è stato condotto in oltre 500 pazienti adulti per 52 settimane1. II disegno innovativo dello studio EGALITY prevedeva 4 bracci di trattamento due di switch (passaggi) e due di trattamento continuo. I pazienti sottoposti allo switch sono passati dal trattamento con biosimilare e prodotto originator 3 volte senza che siano state registrate differenze sostanziali in termini di sicurezza, efficacia ed immunogenicità.“Sandoz riconosce l’importanza per i clinici di avere dati robusti a supporto dello switch per utilizzare in maniera sicura i biosimilari. Nello studio EGALITY gli stessi pazienti sono stati trattati con il biosimilare etanercept alternato con il prodotto originator e questi 3 switch di trattamento non hanno avuto alcun impatto in termini di sicurezza ed efficacia” afferma Malte Peters, Head Global Clinical Development Biopharmaceuticals, Sandoz. “Questo studio innovativo dimostra che Sandoz sta lavorando per costruire fiducia nei farmaci biosimilari in modo tale da garantire un più ampio accesso alle cure per i pazienti di tutto il mondo”, continua Peters.Lo studio EGALITY è un trial randomizzato in doppio-cieco che ha coinvolto 531 pazienti con psoriasi a placche di grado moderato o severo e che è stato condotto in 74 cliniche dermatologiche in 11 nazioni europee e in Sud Africa e consiste in tre diverse fasi di osservazione. Nelle prime 12 settimane i pazienti hanno ricevuto etanercept biosimilare o l’originator. Nella seconda fase i pazienti che avevano mostrato un miglioramento di almeno il 50% dei sintomi della psoriasi sono stati ri-randomizzati in 4 gruppi: i primi 2 gruppi hanno continuato con il trattamento con l’originator o con il biosimilare e gli altri due hanno effettuato switch multipli alternando originator e biosimilare ogni 6 settimane fino alla settimana 301. Nella terza fase di osservazione i pazienti di tutti i quattro gruppi hanno continuato ad essere trattati con l’ultimo trattamento somministrato dalla settimana 30 alla settimana 52.A 52 settimane dall’inizio del trattamento, l’indice di severità PASI (Psoriasis Area Severity Index) è risultato comparabile tra etanercept biosimilare e l’originator.
EGALITY inoltre conferma un profilo di sicurezza paragonabile tra i due trattamenti a 52 settimane, con un simile tasso di incidenza di eventi avversi osservati in tutti i bracci dello studio. L’endpoint primario che consisteva nel raggiungere l’equivalenza nel tasso di risposta PASI 75 sono stati raggiunti alla settimana 122. Questi dati sono stati presentati al congresso Psoriasis International Network (PIN), 2016.L’FDA ha approvato etanercept biosimilare Sandoz nell’agosto 2016, per tutte le indicazioni incluse nel riassunto delle caratteristiche di prodotto dell’originator, per la terapia di diverse condizioni infiammatorie tra cui l’artrite reumatoide, la psoriasi a placche e l’artrite psorisiaca. Etanercept biosimilare Sandoz è sottoposto a revisione regolatoria EMA dopo che la sottomissione è stata accettata nella seconda metà del 2015. L’impegno di Sandoz è volto a incrementare l’accesso dei pazienti a farmaci biologici di alta qualità. Sandoz dispone di una ricca pipeline e ha in programma di lanciare i biosimilari di 5 dei maggiori biologici oncologici e immunologici nelle aree geografiche chiave entro il 2020. Sandoz, divisione del gruppo Novartis, è in un’ottima posizione per guidare il futuro mercato dei biosimilari, grazie alla sua profonda esperienza e competenza nello sviluppo, produzione e commercializzazione di questi farmaci.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Nuove tecnologie e test genetici

Posted by fidest press agency su mercoledì, 2 marzo 2011

Roma. dal 4 al 6 marzo a High Technology in Dermatology, ovvero le tecnologie e i test genetici più avanzati applicati alla cura della pelle, questo in sintesi il tema del 2° Meeting Internazionale dell’ISPLAD che si terrà questa settimana. L’ISPLAD, International-Italian Society of Plastic-Regenerative and Oncologic Dermatology,  da sempre ha fatto della lotta all’invecchiamento cutaneo la propria missione. La cura della pelle, d’altra parte, è anche l’interesse trasversale di milioni e milioni di persone – donne e uomini – perché tutti vogliono vivere a lungo, ma nessuno vuole invecchiare. “Cura e bellezza che innanzi tutto passano dalla salute – afferma Antonino Di Pietro – Presidente Fondatore dell’ISPLAD – quindi nessun miglioramento estetico che trasformi o inibisca le funzionalità, quanto piuttosto contribuire a migliorare le funzioni biologiche cutanee. In tale direzione opera la dermatologia plastica rigenerativa che mira a preservare l’equilibrio ottimale (l’omeostasi)  delle reazioni biologiche che mantengono trofica e funzionale la cute. Negli ultimi anni la ricerca scientifica e le nuove tecnologie hanno messo a disposizione  strumenti e metodiche innovative che agiscono in modo specifico e integrato per rivitalizzare e stimolare derma ed epidermide.  Si parla di protocolli combinati antiage perché nella lotta all’invecchiamento cutaneo non esiste un unico trattamento, ma una vera e propria strategia terapeutica data dall’insieme di strumenti quali la nutri genomica, la lipidomica che danno informazioni utili per intervenire in modo mirato.

Posted in Cronaca/News, Medicina/Medicine/Health/Science, Roma/about Rome | Contrassegnato da tag: , , , | Leave a Comment »